Identification mutations in epidermal growth factor receptor may predict response to gefitinib in NSCLC

Choo-Kang, B. S. W.
July 2004
Thorax;Jul2004, Vol. 59 Issue 7, p607
Academic Journal
Gefitinib targets the tyrosine kinase epidermal growth factor receptor (EGFR) but the presence of EGFR on tumour cells does not predict response to treatment and in clinical trials only a few patients with non- small cell lung cancer (NSCLC) show any response. In this study the authors sequenced the EGFR gene in NSCLC tumours and found somatic mutations in the tyrosine kinase domain in eight of nine patients who had responded to treatment with gefitinib. Mutations were not found in matched normal tissue from these patients, or in seven patients who had no response to gefitinib. When the most common mutation was transfected into cell lines, enhanced tyrosine kinase signalling was seen in response to EGF compared with the wild type gene and there was an increased sensitivity to in vitro inhibition by gefitinib.


Related Articles

  • Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibitor CO-1686.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article informs about the commencement of clinical study of CO-1686, inhibitor of epidermal growth factor receptor (EGFR) mutations, by Clovis Oncology Inc. It informs that the study is directed for treatment of nonsmall cell lung cancer. It mentions of the study being conducted at five U.S....

  • Erlotinib in Lung Cancer – Molecular and Clinical Predictors of Outcome. Tsao, Ming-Sound; Sakurada, Akira; Cutz, Jean-Claude; Zhu, Chang-Qi; Kamel-Reid, Suzanne; Squire, Jeremy; Lorimer, Ian; Zhang, Tong; Liu, Ni; Daneshmand, Manijeh; Marrano, Paula; da Cunha Santos, Gilda; Lagarde, Alain; Richardson, Frank; Seymour, Lesley; Whitehead, Marlo; Ding, Keyue; Pater, Joseph; Shepherd, Frances A. // New England Journal of Medicine;7/14/2005, Vol. 353 Issue 2, p133 

    Background: A clinical trial that compared erlotinib with a placebo for non–small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were...

  • A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Asahina, H.; Yamazaki, K.; Kinoshita, I.; Sukoh, N.; Harada, M.; Yokouchi, H.; Ishida, T.; Ogura, S.; Kojima, T.; Okamoto, Y.; Fujita, Y.; Dosaka-Akita, H.; Isobe, H.; Nishimura, M. // British Journal of Cancer;10/23/2006, Vol. 95 Issue 8, p998 

    Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced...

  • New EGFR Inhibitor Shows Promise Against Small Cell Lung Cancer. Kelly, Janis // Pulmonary Reviews;Mar2008, Vol. 13 Issue 3, p15 

    This article discusses a study presented at the American College of Chest Physicians' 2007 Annual International Scientific Assembly which showed the possible use of epidermal growth factor receptor (EGFR) inhibitors in treating small cell lung cancer (SCLC). The study found that EGFR-related...

  • Erlotinib in Previously Treated Non—Small-Cell Lung Cancer. Shepherd, Frances A.; Rodrigues Pereira, José; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjak, Andrea; Clark, Gary; Santabárbara, Pedro; Seymour, Lesley // New England Journal of Medicine;7/14/2005, Vol. 353 Issue 2, p123 

    Background: We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. Methods: Patients with...

  • Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Verduyn, S. Cora; Biesma, Bonne; Schramel, Franz M. N. H.; van der Scheer, Feike W.; Langenfeld, Merel K.; de Peuter, Maria A.; Dingemans, Anne-Marie C. // Health & Quality of Life Outcomes;2012, Vol. 10 Issue 1, p108 

    Background: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib...

  • Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer--How to Handle Stage I Disease. Wakelee, Heather; Dubey, Sarita; Gandara, David // Oncologist;Mar2007, Vol. 12 Issue 3, p331 

    The standard of care for resected stage II-IIIA non-small cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens--the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and...

  • Consequences of targeted treatments for second-line therapy. De Maio, E.; Tibaldi, C.; D'Incecco, A.; Bursi, S.; Barbara, C.; Cupini, S.; Di Marsico, R.; D'Arcangelo, M.; Landi, L.; Minuti, G.; Cappuzzo, F. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii234 

    The paradigm for first-line treatment of relapsed or metastatic non-small cell lung cancer (NSCLC) is changing. Large phase III trials demonstrated that, in 2010, we cannot select a therapy without an accurate definition of tumor histology and epidermal growth factor receptor (EGFR) status....

  • Targeting EGFR in Non—Small-Cell Lung Cancer. Doroshow, James H. // New England Journal of Medicine;7/14/2005, Vol. 353 Issue 2, p200 

    The article focuses on the author's views on the use of small-molecule inhibitors of the epidermal growth factor receptor (EGFR), like erlotinib and gefitinib, for the treatment of advanced non-small-cell lung cancer. The author suggests that the advent of erlotinib and gefitinib generated wide...


Read the Article


Sign out of this library

Other Topics